DUBLIN (AP) _ Jazz Pharmaceuticals PLC (JAZZ) on Tuesday reported third-quarter profit of $149.3 million.
The Dublin-based company said it had profit of $2.41 per share. Earnings, adjusted for asset impairment costs and stock option expense, were $3.58 per share.
The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $3.33 per share.
The drugmaker posted revenue of $469.4 million in the period, which did not meet Street forecasts. Eight analysts surveyed by Zacks expected $482.1 million.
Jazz expects full-year earnings in the range of $12.75 to $13.25 per share, with revenue in the range of $1.86 billion to $1.9 billion.
Jazz shares have increased 22 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $164.41, an increase of 17 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on JAZZ at https://www.zacks.com/ap/JAZZ